Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 12/20 | 0.41 |
| ▸ | BRD4 | O60885 | 11/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16745964 | 0.74 | BRD4 (0.44) | BRD4NOS2LMNAGAAMAPT | |
| SCHEMBL20180674 | 0.74 | NISCH (0.49) | CREBBPBRD4EP300RAB9ATSHR | |
| SCHEMBL29660000 | 0.66 | CREBBP (0.59) | CREBBPBRD4EP300RAB9ATSHR | |
| SCHEMBL6419356 | 0.66 | CREBBP (0.59) | CREBBPBRD4EP300RAB9ATSHR | |
| SCHEMBL1868013 | 0.63 | CREBBP (0.55) | CREBBPBRD4EP300RAB9ATSHR | |
| SCHEMBL12837999 | 0.63 | CREBBP (0.55) | CREBBPBRD4EP300RAB9ATSHR | |
| SCHEMBL1736809 | 0.63 | CREBBP (0.55) | CREBBPBRD4EP300RAB9ATSHR | |
| SCHEMBL33268 | 0.63 | CREBBP (0.55) | CREBBPBRD4EP300RAB9ATSHR | |
| SCHEMBL29572486 | 0.63 | CREBBP (0.55) | CREBBPBRD4EP300RAB9ATSHR | |
| SCHEMBL16746009 | 0.63 | BRD4 (0.59) | CREBBPBRD4EP300RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624244-B2 | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150148333-A1 | BENZO [B] ISOXAZOLOAZEPINE BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148333-A1 | BENZO [B] ISOXAZOLOAZEPINE BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRD3, BRD2 | CREBBP 16/4885BRD4 1/4885EP300 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.